Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Bioengineering (Basel, Switzerland)
|
August 25, 2022
Laser Bioprinting of Cells Using UV and Visible Wavelengths: A Comparative DNA Damage Study
Panagiotis Karakaidos, Christina Kryou, Nikiana Simigdala, et al.
Methods (San Diego, Calif.)
|
April 17, 2014
Large-scale imaginal disc sorting: A protocol for "omics"-approaches
Florian Marty, Claudia Rockel-Bauer, Nikiana Simigdala, et al.
Plos One
|
June 17, 2016
Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation
Stephanie K Guest, Ricardo Ribas, Sunil Pancholi, et al.
British Journal of Cancer
|
July 12, 2018
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease
Nikiana Simigdala, Sunil Pancholi, Ricardo Ribas, et al.
Breast Cancer Research : BCR
|
June 2, 2016
Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer
Nikiana Simigdala, Qiong Gao, Sunil Pancholi, et al.
NPJ Breast Cancer
|
November 29, 2022
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
Sunil Pancholi, Nikiana Simigdala, Ricardo Ribas, et al.
Plos One
|
July 11, 2013
The hemolymph proteome of fed and starved Drosophila larvae
Björn Handke, Ingrid Poernbacher, Sandra Goetze, et al.
Cellular and Molecular Life Sciences : CMLS
|
March 18, 2023
Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer
Nikiana Simigdala, Anna Chalari, Aimilia D Sklirou, et al.
Breast Cancer Research : BCR
|
February 2, 2020
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
Sunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, et al.
Breast Cancer Research : BCR
|
June 24, 2025
Correction: Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer
Ricardo Ribas, Sunil Pancholi, Aradhana Rani, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Bioengineering (Basel, Switzerland)
|
August 25, 2022
Laser Bioprinting of Cells Using UV and Visible Wavelengths: A Comparative DNA Damage Study
Panagiotis Karakaidos, Christina Kryou, Nikiana Simigdala, et al.
Methods (San Diego, Calif.)
|
April 17, 2014
Large-scale imaginal disc sorting: A protocol for "omics"-approaches
Florian Marty, Claudia Rockel-Bauer, Nikiana Simigdala, et al.
Plos One
|
June 17, 2016
Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation
Stephanie K Guest, Ricardo Ribas, Sunil Pancholi, et al.
British Journal of Cancer
|
July 12, 2018
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease
Nikiana Simigdala, Sunil Pancholi, Ricardo Ribas, et al.
Breast Cancer Research : BCR
|
June 2, 2016
Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer
Nikiana Simigdala, Qiong Gao, Sunil Pancholi, et al.
NPJ Breast Cancer
|
November 29, 2022
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
Sunil Pancholi, Nikiana Simigdala, Ricardo Ribas, et al.
Plos One
|
July 11, 2013
The hemolymph proteome of fed and starved Drosophila larvae
Björn Handke, Ingrid Poernbacher, Sandra Goetze, et al.
Cellular and Molecular Life Sciences : CMLS
|
March 18, 2023
Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer
Nikiana Simigdala, Anna Chalari, Aimilia D Sklirou, et al.
Breast Cancer Research : BCR
|
February 2, 2020
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
Sunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, et al.
Breast Cancer Research : BCR
|
June 24, 2025
Correction: Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer
Ricardo Ribas, Sunil Pancholi, Aradhana Rani, et al.
Page
of 2